• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The method of obtaining 2- - (difeshmethylene) 1 -piperidinyl | .- acetic acid derivatives of the general formula I 1 0 gCN, it is a national derivative of. F-diphenylmethyenJ-1-piperidinyl acetic acid of the general formula 1 1 where the Hit has the indicated value; U is -NHa or the group - OR, where R is lower alkyl, is hydrolyzed in an aqueous-alcoholic medium in the presence of an inorganic base, and the filter product is isolated in free form or as a hydrochloride.
    公开号:SU1176836A3
    申请号:SU813331800
    申请日:1981-09-16
    公开日:1985-08-30
    发明作者:Родригез Людовик；Бальтес Эжен
    申请人:Юцб Са (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to a process for the preparation of new derivatives of (diphenylmethyl en) -1-piperidinyl D-acetic acid of the general formula
    C QN-t-.
    About HE where X is a hydrogen atom or a fluorine atom m 1 or 2,. or their chlorohydrates with antihistamine and bronchodilator properties. These compounds may be used in medicine. Derivatives of 4- (diphenylmethylene) piperidines are known to have antihistamine and bronchodilatory properties, as well as affecting the central nervous system. A typical compound is 2- | 2- 2- 4- (diphenylmethylene) -1-piperidinyl ethoxy ethoxy-ethanol hydrochloride. A disadvantage of the known compounds is their high toxicity and side sedative effects in relatively small doses. A known method for the production of carboxylic acids by hydrolysis from complex, / / cn3, where the Heath has the indicated value; U - —NK2 or the group —OR, where R is lower alkyl, is hydrolyzed in an aqueous-alcoholic medium in the presence of an inorganic base, and the desired product is isolated in free form or as hydrochloride. The hydrolysis is carried out in the presence of an inorganic base such as sodium or potassium hydroxide, in an aqueous-alcoholic medium (methanol, III where Healy m has the indicated values, R is lower alkyl; Z is a halogen atom. So, 1 can be methyl or ethyl, and Z atom of chlorine or bromine. Such a reaction is usually carried out by heating up to 80-150 ° C for ethers and amides. The reaction is carried out at room temperature to the boiling point of the reaction mass 2. The purpose of the invention is to develop a method based on the preparation of new derivatives (diphenylmethylene) -I-piperidinyl-acetic acid or their chlorohydrates with improved pharmacological properties. The goal is achieved by the method of obtaining new 2- (4- (diphenylmethylene) -1-piperidinyl-1-acetic acid derivatives of general formula I or their chlorohydrates, including that a functional derivative of 2-L4- (diphenylmethylene) -1-piperidinyl - acetic acid of the general formula Y NOL, etc., at a temperature from to the boiling point of the reaction mixture. The esters of the formula II, in which the Y -OR used as starting materials for the preparation of the acids of the formula I according to the indicated method, can be obtained by the following methods, E-1. By reacting 4- (diphenylmethylene) -piperidine of formula III with omega-halogenoacetate of lower alkyl of formula IV according to the equation 2CH20 CH2C, for several hours in an inert solvent, which can be one of aliphatic alcohols, benzene, toluene or xylene in the presence of an acid acceptor, for example, a tertiary organic base (eg, triethylamine) or a mineral
    bases (e.g. sodium carbonate).
    . By reacting the alkali metal salt omega-p4- (difensh1
    methyl en) -1-piperidini: L.-ethanol of the formula V with lower alkyl haloacetate of the formula VI according to the equation
    CH2Cf
    0
    YU
    OR
    VI where R, X and m have the indicated signs. cheny; Z is a halogen atom; Me - alkali metal. The reaction between the alkali metal salt of the formula V and the haloacetate of the formula VI is carried out in an inert solvent at a temperature between and the reflux temperature of the reaction mixture. The alkali metal salt used in the reaction is formed in situ as a result of the interaction of the corresponding omega-4- (diphenylmethylene) -1-piperidinyl-D-ethanol with schie, + Zf CH where X and m have the indicated values; Z is a halogen atom. Typically, this reaction is carried out by heating to 80-150 ° C for several hours in an inert solvent selected from the series of aliphatic alcohols, benzene, toluene, or xylo-Q in the presence of an acid acceptor, which can be a tertiary organdy metal (usually with a hydride sodium) in an inert solvent, which may be toluene, xylene or dimethylformamide. The method for producing the pro-, ethanol derivative of the formula V (Me-H) is known. Amides of formula II, where Y is NK used as raw materials for the preparation of acids of formula I according to the indicated method, can be synthesized by various methods. A-1. By reacting 4- (diphenylmethylene) -piperidine of formula III with the omega-haloacetamide of formula VII according to the equation, the CH2O2 base (for example, triethylamine) or the mineral base (for example, sodium carbonate). A-2. By reacting the alkali metal salt omega-.4- (diphenylmethylene) -1-piperidinylD-ethanol of formula V with 2-halogenoacetamide of formula VIII according to the equation CH2CH20 Me -f Z - SNgC
    , 0
    (W
    Nn
    tVIII)
    1de X and ha have the indicated meanings;
    Z is a halogen atom;
    Me - alkali metal.
    The reaction between the alkali metal salt of the formula V and the halocetamide of the formula VIII is carried out in an inert solvent at a temperature of from 0 ° C to the reflux temperature of the reaction mixture.
    Chlorohydrates can be obtained by converting compounds of formula I using conventional synthesis methods.
    Preparation of the starting esters of formula II.
    Obtaining ethyl ether (diphenylmetsh1en) -1-piperidineNILD ETOXY ETOXIDE-acetic acid solution 207.6 g (about, 616 mol) 2- (diphenylmethylene) -1-piperidinyl1 ETOXI of ethanol. In 1, 2 l of anhydrous toluene cool down cooled down 17.5 g are added to it in portions (O, 729 mol of sodium hydride. 35 g of the suspension is a hydride, sodium read in paraffin waxes. 50% of it is washed three times with anhydrous toluene. The mixture is slowly heated and kept at this temperature 2 hours. Then it is cooled in a nitrogen atmosphere to 0 ° C, and maintaining this temperature, 122 g (0.73 mol) of methyl bromide are introduced. At the end of the introduction of ethyl acetate, the reaction mixture is kept at 40 ° C for 4 hours and then cooled to ambient temperature. The precipitate is filtered and washed with a small amount of toluene. After evaporation of the filtrate, a precipitate of 345.6 g of ethyl ether remains ( diphenylmethylene) -1-piperidinitL etho sy 3TOKcti | -yKcycHou acid used in example 1-1 without further purification. E-1. A mixture of 24.93 g of 4- (diphenyl methylene) -piperidine, 32 g of ethyl G2- (2 T-chloroethoxy) ethoxy | -acetate and 18 g of anhydrous sodium carbonate in 80 ml of xylene are kept for 20 hours at 90-110 ° C. The precipitate is filtered. The filtrate is extracted with a dilute hydrochloric acid solution and the aqueous phase, after alkalinization, is extracted with benzene and the concentrated sodium hydroxide solutions. The benzene phase is evaporated in vacuo and the resulting precipitate (ether) is used in Example 1-2 without further purification. Used in this synthesis, ethyl G2- (2-chloroethoxy) ethoxy-acetate is prepared as follows. A solution of 100 g of 2- (2-chloroethoxy) ethoxy-aceto-nitrile in 500 ml of ethanol is saturated in the cold with gaseous hydrogen chloride. The mixture is heated to reflux with -NICOM for 5 h, then distilled. Yield 81.2%, kp. 146-148 ° C / 15 mm Hg Preparation of ethyl 2- 2- 4- (diphenyl methylene) -1-piperidinyl ethoxy-acetic acid. This ester is prepared according to the method of E-1 using ethyl (2-chloroethoxy) -acetate and 4- (diphenylmethylene) -piperidine. It was used without additional purification to obtain the corresponding acid (Example 1-3). Preparation of the original amido. In formula II. 1. Preparation of (difensh1methylene) -1-piperidinyl-ethoxy ethoxy-acetamide (method A-1). A mixture of 29.9 g of 4- (diphenylmethylene) -piperidine, 36.3 g of 2-- 2-; is heated for 20 hours at 90-110 ° C. 2-chloro ethoxy) ethoxy-acetamide and 18 g sodium carbonate in 80 ml xylene. Then 80 ml of benzene are added, the precipitate is filtered and the organic layer is extracted with a dilute hydrochloric acid solution (20 ml of concentrated hydrochloric acid in 80 ml of water). After adding 30 ml of a concentrated sodium hydroxide solution and extracting with benzene, the benzene solution is washed, dried over potassium carbonate and benzene is evaporated in vacuo. The resulting 4- (diphenylmethylene) -1 - piperidinyl-ethoxyT ethoxy-acetamide is used to prepare the corresponding acid (Example 1-4) without further purification. The (2-chloroethoxy) ethoxy-acetamide used in this synthesis is obtained by the known method. Yield 77%, mp. 51-53c. Preparation of 2-4- (4-fluorophenyl) phenylmethylene-β-piperidinyl ethoxy-acetamide. This product is obtained according to method A-1. Yield 65%, mp. 118-119 ° C. Calculated,%: C 71.71; H 6.84; N, 7.60; Found: C, 71.66; H 6.93; N 7.53. Example 1. Preparation of acids of formula I. 1-1. 2- 2- 2--14- (diphenylmethylene -1-piperidinyl ethoxyT ethoO / 4-1 -acetic acid) hydrochloride. 345.6 g of ethyl 2- 2-L2-4- (diphenylmethylene) -1-piperidinyl ethoxyT ethoxy - acetic acid is dissolved in 0.9 l of ethanol. This solution is added to a solution of 288 g of potassium hydroxide in 1.5 liters of water. Alcohol 98 ° C (distilled at column temperature). Then the reaction medium is evaporated to dryness and the precipitate is mixed with anhydrous toluene. As a result, two phases and a small amount of solid are obtained. The toluene phase is separated and evaporated. 291.5 g of precipitate are obtained. is created in 1.5 liters of isopropyl alcohol, in which 137 ml of an alcoholic solution of hydrochloric acid (4.91 n) is added at 20 ° C. The solution is evaporated to dryness and the residue is recrystallized from acetonitrile, then from isopropyl alcohol. 104 g of 4- (diphenylmethylene) -1-piperidinyl-J ethoxy ethoxy-acetic acid hydrochloride are obtained in a yield of 39%, mp 139-140 ° C. Calculated,%: C, 66.7; H, 6.95; N 3 , 24; C 8.40; .CS1 Found,%: C 66.62; H 6.95; N 3.27; C1 8.21. 1-2. The acid obtained in Example 1-1 can also be prepared from this ester, prepared by Method E-1. : The precipitate (ester) obtained by the meth- od duster after evaporation in vacuo is dissolved in 100 ml of ethanol and 23 ml of sodium hydroxide (3.95 N). After. one and a half hours heating under reflux the reaction mixture is neutralized with 20.7 ml of hydrochloric acid (4.38 N), and the ethanol is removed by evaporation in vacuo. The precipitate is extracted with dichloromethane, the organic phase is evaporated to dryness after drying over sodium sulfate. The precipitate is stirred for one hour with 100 ml of ethyl acetate and allowed to crystallize c. 13.4 g of (diphenylmethylene) -1-piperidinyl-ethoxy ethoxyD-acetic acid are obtained. The output of 67.5%, so pl. 120-123 ° C. 1-3. (Diphenyl methylene) -1-piperidinyl-J ethoxy-acetic acid hydrochloride is prepared in Example 1-2-but-OUT of 4- (diphenylmethylene) -1-piperidine T-ethoxyD-acetic acid ethyl ester, prepared as described above. Yield 71%, t.gsh. 193-194 ° C. Calculated,%: C 68.12;; H 6.75; N 3,61; SG 9.14. CjjEjj-NO, - HC1 Found,%: C 67.37; H 6.78; N 3.56; SG 8.93. 1-4.2- {2- 2- 4- (Diphenylmethylene) -1 -. -piperidinyl ethoxy ethoxy-acetic acid. (Diphenylmethylene) -1-piperidinyl ethoxy ethoxyDacetamide is dissolved in 120 ml of ethanol. 60 ml of an aqueous solution of sodium hydroxide (3.95 N) are added and the mixture is boiled for 1.5 hours. After cooling, the mixture is neutralized by adding 54 ml of hydrochloric acid (4.38 N) and ethanol is evaporated in vacuo. The resulting solution is extracted with dichloromethane, dried over sodium sulfate and evaporated to dryness. The precipitate is stirred with 50 ml of ethyl acetate and left to crystallize. 38 g of 2- 2- 2- (4-diphenylmethylene) -l-piperidinyl ethoxyJethoxyJ-ycyclic acid are obtained. The resulting product is identical to the product synthesized in example 1-2. Output 80%, so pl. 121-123 ° C. Calculated,%: C, 72.88; H 7.39; N3.54, C Found,%: C 71.42; H 7.45; N 3.57. 1-5. (4-Fluorophenyl) phenylmethyl en -1 -piperidinyl | ethoxy acetic acid was prepared in Example 1-4 by hydrolysis of (4-fluorophenyl) phenylmethylene 1-1-piperidinyl 2 ethoxy acetamide. Yield 96%; m.p. 72-74 ° C. Calculated,%: C 71.52; H 6.52; N 3.74. Found,%: C 71.05; H 6.05; N 3.90. Mass spectrum: ionized molecule M + m / e 369. Pharmacology: the following products obtained in accordance with the invention were subjected to pharmacological tests: hydrochloride 2 -2-2-2-G4- (diphenylmethylene) -1 -piperidine w ethoxy ethox α-acetic acid (product A obtained in example 1 -1 /); 2-C2-14- (diphenylmethylene) -1-piperidinylTethoxy-acetic acid hydrochloride (the product in, obtained in a measure of 1-3); (4-fluorofensh1) phenylmethylene | 1 71-piperidinyl 1 ethoxy | acetic acid (product C, obtained in Example 1-5). For comparison, the well-known chloro-hydrate (diphenylmethyl) -piperidinylT ethoxy ethoxyethanol (product X) is taken. Antitistaminic activity. Conzett and Roessler measured this activity on sea guinea pigs, and also compared with theophylline and product X. A system of artificial respiration was put to the sleepy and prone guinea pig. The endotracheal pressure is recorded with instruments. Repeated bronchial spasms are excited by successive and gradually increasing doses of histamine in doses. Subject to the test substance is also administered intravenously. Below are the doses of injected products, which, on average, in 50% of experimental animals eliminate excitatory spasms of the bronchi, / kg / kg: Theophyllin 2650 X70 A47 B37 C58 From the data it follows that X-derived products have valuable activity in relation to bronchial spasms caused by histamine. In addition, this test revealed that some compounds, administered in an unchanged amount, are characterized by prolonged antihistamine activity. For example, product A, administered intravenously to a guinea pig in an amount of 0.1 mg / kg, after an hour, continues to possess 61% anti-histamine activity. And the same amount of product X 30 minutes after administration does not have an antihistamine effect. Bronchodilatory effect. Investigated on the dog with the pilocarpine dog test. An artificial respiration system is fed to a dog euthanized and exposed to curare. Endotracheal pressure is recorded with instruments. Constant respiratory spasms are excited by continuous intravenous perfusion of pilocarpine. Subjects to be tested are also administered intravenously. At a dose of 320 lg / kg: product A reduces by 57% (on average, the total number of experimental animals) the intensity of the spasms being excited. Theophylline, administered in 10-fold size (3200 mg / kg), reduces only 35% the intensity of the spasms excited: product X at a dose of 320 mg / kg reduces spasms by only 43%. 7 Thus, product A has a more significant bronchodilator activity than theophylline or product X. General behavior of mice / Irwin test). It was investigated using the test Irwin. Gradually increasing doses of the test substance are administered within the peritoneal group consisting of three male mice (weight 18-22 g), and the behavior of the animals is studied on the basis of classical criteria. For comparison, the following substances are taken: hydroxyzine: 1 - (p-chloro-alpha-phenyl-benzyl) -4- (2-hydroxy-toxyethyl) -piperazine; oxazepam: 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1, 4-benzodia: zePIN-2-OH. Below are the doses that cause the first sph) of sedation in animals, mg / kg: Hydroxysin 27 Oxazepam2,6 X.19,5 A130 B105 SPO Thus, the products obtained according to the invention have a slight sedative effect compared to the commonly used means in particular, compared with substance X. In addition, as a result of this test, the toxicity of the products obtained in accordance with the invention is found to be weak. The following are data on the toxicity of substances
    权利要求:
    Claims (2)
    [1]
    The method of obtaining derivatives
    [2]
    2- [4- (diphenylmethylene) -1-piperidinyl) ---------- the general form of acetic acid 1 where X is a hydrogen atom or a fluorine atom; the functional derivative '2- £ 4 m = 1 or 2, is diphenipomethylene) - 1 - piperidinyl ^ or their chlorides and hydrates, and t - and - acetic acid are generally formed by the fact that the functions 1 1 where Xi have the indicated meaning ; Y is —KH— , or a group —OR where R * is lower alkyl, is hydrolyzed in an aqueous-alcoholic medium in the presence of an inorganic base ·, and the target product is isolated in the free form or in the form of hydrochloride.
    类似技术:
    公开号 | 公开日 | 专利标题
    US3806526A|1974-04-23|1-aroylalkyl-4-diphenylmethyl piperidines
    JP3880842B2|2007-02-14|Enantiomers of 1-[| phenylmethyl] piperazine and process for producing the same
    US4675319A|1987-06-23|Antianaphylactic and antibronchospastic piperazinyl-|carboxamides, compositions and use
    US4788191A|1988-11-29|1,3-dithiolano-, 1,4-dithiino- and 1,4-dithiepino[2,3-C]pyrrole derivatives, their production and use
    SU1176836A3|1985-08-30|Method of producing derivatives of 2-|-1-piperidinyl)-methanecarboxylic acid or chlorohydrates of thereof
    AU630178B2|1992-10-22|4|-pteridinones, preparation processes and drugs containing them
    RU1836359C|1993-08-23|Method for obtaining pyrimidine-4,6-dicarboxylic acid diamides
    JP2011063619A|2011-03-31|Acid addition salt of optically active piperidine derivative and process for producing the same
    US4908365A|1990-03-13|Benzhydryloxyethylpiperazine derivatives, processes for their preparation and pharmaceutical compositions in which they are present
    US4578481A|1986-03-25|Pyrrolacetic amides having antiinflammatory activity
    EP0097821A2|1984-01-11|Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them
    HU221811B1|2003-01-28|N-acylated piperidine derivatives, process for producing them, and pharmaceutical compositions containing them
    US4560692A|1985-12-24|4-Piperidino-2-phenylquinolines
    US4341893A|1982-07-27|Quinazoline derivatives
    US4529730A|1985-07-16|Piperidine derivatives, their preparation and pharmaceutical compositions containing them
    EP0470686B1|1996-05-15|aliphatic acid derivatives and their use in the treatment of allergies and asthma
    US4529729A|1985-07-16|Piperazine and homopiperazine compounds
    IE55377B1|1990-08-29|1,5-diphenylpyrazolin-3-one compounds,method for preparing them,and pharmaceutical compositions containing these compounds
    GB2153825A|1985-08-29|Trypsin-inhibiting arginine derivatives
    JP2725378B2|1998-03-11|Carbamate derivatives
    US3644368A|1972-02-22|Novel quinolines
    US4069323A|1978-01-17|N2 -substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
    EP0094065B1|1989-12-20|2-aminobenzoic acid derivatives, a process for their preparation and pharmaceutical compositions
    HU179951B|1983-01-28|Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof
    CS195652B2|1980-02-29|Method of producing new 4-diphenylmethylen-1-hydroxy-benzylpiperidines
    同族专利:
    公开号 | 公开日
    NO157931B|1988-03-07|
    SU1108090A1|1984-08-15|
    JPS5782369A|1982-05-22|
    ES8305750A1|1983-04-16|
    FI74950B|1987-12-31|
    DE3164741D1|1984-08-16|
    AU539568B2|1984-10-04|
    HK14086A|1986-03-07|
    DK408781A|1982-03-19|
    AU7543681A|1982-03-25|
    NO157931C|1988-06-15|
    AT8388T|1984-07-15|
    PL128505B1|1984-02-29|
    ES8301213A1|1982-11-16|
    FI74950C|1988-04-11|
    YU222481A|1984-02-29|
    EP0048705A1|1982-03-31|
    ES505568A0|1982-11-16|
    US4443460A|1984-04-17|
    SU1179922A3|1985-09-15|
    YU43038B|1989-02-28|
    CA1167446A|1984-05-15|
    PL233059A1|1982-10-11|
    PL128590B1|1984-02-29|
    DK149133C|1986-09-08|
    CY1312A|1986-03-28|
    EP0048705B1|1984-07-11|
    JPH0121144B2|1989-04-19|
    FI812852L|1982-03-19|
    ES513867A0|1983-04-16|
    DK149133B|1986-02-10|
    MY8600341A|1986-12-31|
    ZA816462B|1982-09-29|
    HU185313B|1985-01-28|
    NO813119L|1982-03-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2898339A|1957-07-29|1959-08-04|Wm S Merrell Co|N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine|
    US3221018A|1964-04-07|1965-11-30|Aldrich Chem Co Inc|N-cyclopropyl amides of 4-phenyl-1,2,5,6-tetrahydropyridino alkanoic acids and intermediates thereof|
    US3221017A|1964-04-07|1965-11-30|Aldrich Chem Co Inc|Aralkoxyamides of 4-phenyl-1,2,5,6-tetrahydropyridino alkanoic acids and intermediates thereof|
    US3576810A|1968-06-20|1971-04-27|Robins Co Inc A H|1-substituted-3--aroylpiperidines|
    GB1242169A|1969-04-09|1971-08-11|Ucb Sa|Piperidine derivatives|
    US3806526A|1972-01-28|1974-04-23|Richardson Merrell Inc|1-aroylalkyl-4-diphenylmethyl piperidines|
    US3922276A|1974-12-11|1975-11-25|Robins Co Inc A H|1-Substituted-4-benzylidenepiperidines|
    US4251655A|1978-03-29|1981-02-17|Mcneilab, Inc.|Substituted N-iminomethylpiperidines|
    US4285958A|1979-04-10|1981-08-25|Richardson-Merrell Inc.|1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof|
    CH647235A5|1980-02-13|1985-01-15|Sandoz Ag|4- PIPERIDINE DERIVATIVES, THEIR PRODUCTION AND USE.|CH665637A5|1984-12-24|1988-05-31|Wakamoto Pharma Co Ltd|5-TETRAZOLE AS ANTIASTHMATIC AGENT, COMPOSITION CONTAINING IT AND PROCESS FOR PREPARING THE COMPOSITION.|
    EP0228893A3|1985-12-20|1990-01-03|A.H. ROBINS COMPANY, INCORPORATED |Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment|
    US4810713A|1985-12-20|1989-03-07|A. H. Robins Company, Incorporated|Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment|
    JPH0579063B2|1986-08-12|1993-11-01|Wakamoto Pharma Co Ltd|
    FR2603583B1|1986-09-05|1988-12-09|Andre Buzas|BENZHYDRYLOXYETHYL-PIPERIDINE DERIVATIVES, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|
    US5095022A|1989-07-04|1992-03-10|Hokuriku Pharmaceutical Co., Ltd.|Piperidine derivatives and pharmaceutical compositions comprising the same|
    US5000436A|1990-02-26|1991-03-19|Paper Converting Machine Company|Rotary stacker and method|
    US5654433A|1993-01-26|1997-08-05|Merrell Pharmaceuticals Inc.|Process for piperidine derivatives|
    US5631375A|1992-04-10|1997-05-20|Merrell Pharmaceuticals, Inc.|Process for piperidine derivatives|
    CZ168896A3|1995-06-27|1997-01-15|Egyt Gyogyszervegyeszeti Gyar|Oxaindene derivatives and process for preparing thereof|
    US7683077B2|2003-05-20|2010-03-23|Ajinomoto Co., Inc.|Piperidine derivative|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8030194|1980-09-18|
    [返回顶部]